Ustekinumab in psoriatic arthritis and related phenotypes

Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE)

(2018) Florenzo Iannone et al.   CLINICAL RHEUMATOLOGY

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

(2016) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ustekinumab Treatment and Improvement of Physical Function and Health-Related Quality of Life in Patients With Psoriatic Arthritis

(2016) Proton Rahman et al.   ARTHRITIS CARE & RESEARCH

Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture

(2015) Philip E. Stuart et al.   AMERICAN JOURNAL OF HUMAN GENETICS

European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update

(2015) L Gossec et al.   ANNALS OF THE RHEUMATIC DISEASES

Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up

(2015) R.G. Langley et al.   BRITISH JOURNAL OF DERMATOLOGY

Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis

(2015) Philip J. Mease   CURRENT OPINION IN RHEUMATOLOGY

Genetic, Epigenetic and Pharmacogenetic Aspects of Psoriasis and Psoriatic Arthritis

(2015) Darren D. O’Rielly et al.   RHEUMATIC DISEASE CLINICS OF NORTH AMERICA

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

(2014) Christopher Ritchlin et al.   ANNALS OF THE RHEUMATIC DISEASES

Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials

(2014) Arthur Kavanaugh et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

(2013) Iain B McInnes et al.   LANCET

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study

(2012) A.B. Kimball et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

The early phase of psoriatic arthritis

(2011) D. McGonagle et al.   ANNALS OF THE RHEUMATIC DISEASES

The interleukin-17 cytokine family: critical players in host defence and inflammatory diseases

(2011) Rajita Pappu et al.   IMMUNOLOGY

Genome-Wide Meta-Analysis of Psoriatic Arthritis Identifies Susceptibility Locus at REL

(2011) Eva Ellinghaus et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis

(2010) Ulrike Hüffmeier et al.   NATURE GENETICS

Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

(2010) Christopher E.M. Griffiths et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial

(2009) Alice Gottlieb et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET

A Genome-Wide Association Study of Psoriasis and Psoriatic Arthritis Identifies New Disease Loci

(2008) Ying Liu et al.   PLoS Genetics